Tavanic Sanofi solution to treat infections (100ml)

Dosage form Box X 100ml
Specifications Levofloxacin

Ingredient

Composition informationContent
Levofloxacin500mg

Uses

Indications

Tavanic infusion solution indicated treatment in the following cases:

Tavanic is a synthetic antibiotic belonging to the Fluoroquinolon group. The drug works by killing bacterial bacteria in the body.

  • Tavanic infusion solution is indicated to treat cases of infections caused by bacteria sensitive to levofloxacin:
  • pneumonia with community,
  • complex urinary tract infections (including nephritis),
  • Prostatitis of chronic infections,

    Mechanism of impact

    is an antibacterial drug of fluoroquinolon, levofloxacin inhibits the synthetic DNA of bacteria by acting on the DNA-DNA Gyrase and Topoisomerase IV complex.

    Pharmacy and pharmaceutical relationship

    The level of bactericidal activity of levofloxacin depends on the ratio of the maximum concentration of the drug in serum (CMAX) or the area under the curve (AUC) with a minimum inhibitory concentration (Mic).

    resistance mechanism

    resistance to levofloxacin obtained through a step -by -step process by having mutations in the destination position of all types of Topoisomerase TIP II, DNA Gyrase and Topoisomerase TIP IV. Other anti -drug mechanisms such as osmotic barriers (common in Pseudomonas Aeruginosa) and pump mechanisms that can also affect the sensitivity to Levofloxacin. There is a cross -resistance between levofloxacin and other fluoroquinolones. Due to the impact mechanism, usually there is no cross -resistance between levofloxacin and other group antibiotics.

    fractures

    Eucast suggests mic fractures for levofloxacin, here there is a separation of bacterial sensitivity strains with intermediate sensitive bacteria and intermediate sensitive bacteria strains with resistance strains, presented in the table below to check the mic (Mg/L).

    Clinical mic fractures for levofloxacin, according to Eucast (version 2.0, 2012):

    pathogens sensitive level resistance level ≤1 mg/l 2 mg/l

    streptococcus pneumoniae1 ≤2 mg/l 2 mg/l streptococcus a, b, c, g ≤1 mg/l hemophilus influenzae2.3 Brand 4 ≤1 mg/l > 1 mg/l

    2 Fluoroquinolon resistance is low (mic ciprofloxacin is 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is clinically importance in respiratory infections caused by H Influenzae.

    3 strains with mic values ​​on sensitive breaks are very rare or have not been reported. The determination and inspection of the province sensitive to antibiotics for any such isolated strains must be repeated and state the confirmation results, the sample should be sent to the reference lab. Until there is clinical evidence of clinical response to the sagging certified with larger mic than the current fracture, it is necessary to report this antibiotic resistance status.

    4 broken points apply for a dose of 500 mg x 1 to 500 mg x 2 times and one | Intravenous dose of 500 mg x 1 to 500 mg x 2 times.

    When necessary, consult expert advice on local drug resistance ratio about the benefits of this drug in at least some suspected infections.

    Bacterial species are often sensitive

    Gas Gram -positive bacteria:

  • Bacillus anthracis;
  • Staphylococcus aureus is sensitive to methicillin;
  • streptococcus pneumoniae;
  • streptococcus pyogenes.
  • Eikenella Corrodens;
  • Haemophilus Influenzae;
  • Proteus vulgaris Providencia Rettgeri.
  • Anaerobic bacteria:

  • peptostreptoccus.
  • Other:

  • chlamydophila pneumoniae;
  • chlamydophila psittaci;
  • Ureaplasma Urealyticum.

    Aerobic gram -positive bacteria

  • Enterococcus Faecalis;
  • acinetobacter baumannii;
  • citrobacter freundii;
  • Morganella Morganii;
  • Proteus Mirabilis;
  • Bacteroides Fragilis.

    Aerobic gram -positive bacteria:

  • Enterococcus Faecium.
  • #s. Methicillin Aureus is very resistant to fluoroquinolon, including levofloxacin.

    pharmacokinetic

    absorption

    Stable blood concentration is reached within 48 hours after taking 500 mg of levofloxacin once or twice daily.

    distribution

    about 30-40% levofloxacin is associated with serum protein. The average distribution of levofloxacin is about 100 liters after a single dose and repeats 500 mg, showing a wide distribution of drugs into the body tissue.

    penetrates into tissues and fluids

    levofloxacin has been shown to penetrate the bronchial mucosa, epithelium lining, alveolar, lung tissue, skin (fluid in the skin of the skin), prostate tissue and urine. However, Levofloxacin penetrates poorly into the cerebrospinal fluid.

    Biological Change

    Levofloxacin is very small, metabolic substances are desmethyl-levofloxacin and levofloxacin n-oxide. These metabolites account for

    Elimination

    After intravenous injection, levofloxacin is relatively slowly eliminated from plasma (t ½ = 6-8 hours). Excretion mainly through the kidney (> 85% dose). The average average clearance of levofloxacin after a single dose of 500 mg is 175 ± 29.2 ml/min. There is no difference in levofloxacin pharmacokinetics after intravenous injection and after drinking, suggesting that intravenous and oral infusion can be replaced,

    linear properties

    Levofloxacin pharmacokinetics are linearly in the dose range from 50 to 1000 mg.

    Special population

    Object of renal failure: levofloxacin pharmacokinetics affected by kidney failure. Reducing kidney function, elimination function and reduced clearance level reducing the sale time, shown according to the table below:

    Pharmacokinetic pharmacokinetics on the subject of renal failure after a single dose of 500 mg by oral:

    CICR [ML/min] [H] 35 27

    There is no significant difference in pharmacokinetics Levofloxacin among young and elderly subjects, unless people have a difference in creatinine clearance.

    Gender difference:

    separate analysis for male and female subjects shows a small difference in margin for levofloxacin pharmacokinetics. There is no evidence that these gender differences are clinically related.

    Before taking Tavanic Sanofi solution to treat infections (100ml)

    How to use

    Tavanic infusion solution is only used for slow intravenous infusion; The drug is used once or twice daily. Injecting time must be at least 30 minutes for 250 mg of levofloxacin (50 ml of infusion solution) or at least 60 minutes for 500 mg of levofloxacin (100 ml of infusion solution). After a few days, it is possible to switch from in the beginning to oral intravenously to the same dose, depending on the condition of the patient.

    Skin protection avoids sunlight

    It is necessary to avoid direct sunlight during Tavanic. The skin of the patient will be more sensitive to the sun and may suffer from burns, burning or blistering without applying the following precautions

    Use sunscreen with high index.

    Always wear hats and wear long sleeves and pants.

    Avoid sunbathing.

    Dosage

    Tavanic is used once or twice daily. Dosage depends on the type and severity of infection and the sensitivity of the hypothetical pathogen.

    Treatment time

    Duration of treatment varies depending on the type of disease (see below). Like antibiotic treatment in general, it is advisable to continue using Tavanic for at least 48 to 72 hours after the fever is gone or there is evidence of bacterial deduction.

    If you stop using Tavanic

    Do not stop using Tavanic yourself just because the patient feels better. It is important to complete the Tavanic course that the doctor has prescribed.

    If you stop taking Tavanic too early, infection will recur, the condition of the patient may be worse or the bacteria will become resistant.

    Dosage in patients with normal renal function (clearing creatinine> 50 ml/minute):

    Indication
    Dosage daily (depending on heavy levels)
    Treatment time (1) (Depending on the severity) 7-14 days Chronic 500 mg once a day 28 days Time to use drugs through intravenously transferred through oral route is depending on the condition of the patient, usually 2-4 days after the beginning of treatment.

    Caution for patients with renal failure

    Because levofloxacin is mainly excreted in water, reduces the dose in patients with renal failure. Related information is presented in the following table:

    Now Creatinine clearance First dose: 250 mg First dose: 500 mg First dose: 500 mg Next: 250 mg/24 hours next dose: 250 mg/12 hours and continuous peritoneal mobilization*).

    No dose adjustment, because levofloxacin is not metabolized in the liver at any level.

    Elderly patients

    No need to adjust the dose in the elderly, in addition to considering the possibility of renal function decline (see warning and caution when taking the drug).

    Children's patients

    Contraindicated to use Tavanic for children and teenagers is growing.

    Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

    What to do when overdose? Qt.

    Affects the central nervous system including confusion, convulsions, hallucinations, and shaking tremors after being circulated in the market.

    If an overdose occurs, patients should be closely monitored, including ECG testing and symptom treatment should be conducted. Dialysis, including peritoneal and peritoneal fertilizer, is constantly working, not effective to eliminate levofloxacin from the body. There is currently no specific antidote.

    In an emergency, call the 115 emergency center immediately or go to the nearest local health station.

    What to do when forgetting 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

    Side Effects

    The following information is based on data from clinical studies in 8300 patients and based on the experience used after the drug is widely circulated.

    The frequency in this table is defined according to the following convention: Very common (≥1/10), common (≥1/100,

    In each frequency group, unwanted effects are presented in the order of severity. Common organ systems

    (≥1/100 to Less (≥1/1000 to rare (≥1/10000 to
    Unknown (not estimated from existing data) Parasitic and parasitic infections

    Against disease

    Nonflower tank

    Platelet reduction

    Neutral leukemia

    Reduce all blood cells

    grain leukemia

    Hematalate anemia

    Hypersensitivity (see caution when taking the drug)

    Anaphylaxis*

    Anaphylaxis shock* (see caution when taking the drug)

    Metabolic and nutrition disorders

    Sugar sexual coma (see caution when taking the drug)

    Confusion

    Stress

    Mental reactions (for example, hallucinations, paranoia)

    Depression

    excitement

    Unusual dreams

    nightmares

    Psychiatric disorders that have self -dangerous behaviors include ideas or suicidal calculations (see caution when taking drugs)

    dizzy

    drowsy

    Run

    Disorders of taste

    Convulsions (see contraindications and caution when taking drugs)

    Perpetual

    Peripheral sensory neuropathy (see caution when used)

    Modified neuropathy-enlightenment (see caution when taking drugs)

    Smaric disorders include loss of smell

    Movement disorder

    Periodic disorders

    Lost taste

    fainting

    benign intracranial turbocharger

    eye disorders

    Dizziness due to loss of balance

    Tinnitus

    hearing loss

    cardiovascular disorders loss, can lead to. Cardiac arrest

    ventricular and twisted arrhythmia (reports mainly in patients with risk factors for extending the QT), extending the QT distance on the electrocardiogram (see caution when taking the drug and overdose)

    Bronchospasm

    Allergic pneumonia

    vomit

    Nausea

    abdominal pain

    indigestion

    Astonious bloating

    Constipation

    Pancreatitis

    bile liver disorders increased liver enzymes (ALT/AST, alkaline phosphatase, GGT) increased bilirubin in the blood

    jaundice and severe liver damage, including patients with acute liver failure, most patients with patients with drugs should be seriously ill when used)

    Hepatitis

    itch

    urticaria

    Increase sweating

    muscle pain

    Stevens Johnson syndrome

    Diverse roses

    Increase light sensitivity

    White blood vessels in the skin

    stomatitis

    muscle weakness can be especially important in patients with myasthenia gravis (see caution when taking the drug)

    Demonstration

    tendon rupture (for example: Achilles) (see contraindicated and cautious when taking the drug)

    ligament rupture

    muscle break

    arthritis

    kidney and urinary disorders increased blood in the blood acute kidney failure (eg due to interstitial kidney inflammation)

    The response to the infusion (pain, redness)

    Demonstrate
    Fever

    Pain (including back pain, chest, and limbs)

    Warnings

    Before using the drug you need to read the instructions carefully and refer to the information below.

    Contraindicated

    Tavanic infusion solution is contraindicated in the following cases:

  • Patients with allergies to levofloxacin or with any other quinolon antibiotics or allergies to any other component of Tavanic (listed in the ingredient of the formula).
  • Patients who are pregnant.

    Precautions when using

    to be out of reach of children. Please read the instructions carefully before use. Immediately notify the doctor or pharmacist the harmful reactions encountered when using the drug

    Warning

    Serious reactions are likely to not recover and cause disabilities, including tendonitis, tendon, peripheral neuropathy, and adverse effects on the central bodies.

    Fluoroquinolon antibiotics are associated with serious harmful reactions that can cause disabilities and non -recovery on different organs of the body. These reactions may appear simultaneously on the same patient. Harmful reactions are often recorded with tendonitis, tendon, joint pain, muscle pain, peripheral neuropathy, and adverse effects on the central nervous system, anxiety, depression, insomnia, severe headaches and confusion). These reactions may occur within hours to a few weeks after using the drug. Patients of any age or no risk factors that exist before may have these harmful reactions.

    Stop using the drug as soon as there are signs or first symptoms of any serious harmful reactions. In addition, avoid using Fluoroquinolon antibiotics for patients who have had serious reactions related to fluoroquinolon.

    Precautions when taking drugs

    Levofloxacin resistance bacteria

    Staphylococcus aureus bacteria resistant to methicillin (MRSA) are more likely to resist resistance of fluoroquinolones including levofloxacin. Therefore, it is not recommended to use levofloxacin to treat mRSA infections that have been known or suspected unless there is a microbiological test result to confirm the sensitivity of pathogens with levofloxacin.

    Escherichia coli bacteria resistant to fluoroquinolon - the most common pathogens in urinary tract infections, distributed varies by region. The treatment doctor is recommended to pay attention to the ratio of Fluoroquinolon of E.coli in the locality.

    Variasis time

    The recommended intravenous time is at least 30 minutes with a bottle of 50 ml of Tavanic 250 mg or 60 minutes with a bottle of 100 ml of Tavanic 500 mg infusion solution to be followed. There have been cases of increased heart rate and hypotension during the infusion ofloxacin. In some rare cases, as a result of a loss of blood pressure, cardiovascular collapse may occur. While levofloxacin fluid is the transmission co-distribution of Ofloxacin- if there is a significant reduction in blood pressure, it is necessary to stop transmission immediately.

    Sodium content

    This drug contains 7.8 mmol (181 mg) sodium in a dose of 50 ml and 15.8 mmol (363 mg) in a 100 ml dose. Pay attention to patients who are following sodium control diet.

    muscle tendonitis and tendons

    muscle tendonitis rarely occurs. The most common is the heeled tendon (Achilles tendon) and can lead to tendons that can occur within 48 hours after starting treatment with levofloxacin, occasionally being recorded by both sides and has been recorded until several months after stopping treatment. The risk of muscle tendon and tendons increases in patients over 60 years old, in patients inpatient treatment with daily data of 1000 mg and in patients who are taking corticosteroids. Moreover, because patients with organ transplantation increase the risk of muscle tendonitis, caution should be used when using fluoroquinolon in this group of patients. The daily dose must be adjusted in elderly patients based on creatinine clearance. Therefore, it is necessary to monitor these patients closely if treated levofloxacin. All patients must advise their treatment doctor if they have experienced symptoms of muscle tendonitis. If there is a suspected tendonitis, levofloxacin must be discontinued immediately, and the scales start appropriate treatment (e.g. holding immobile) for the affected muscle tendon.

    Clostridium difficile disease

    diarrhea, especially when severe, persistent or without blood, during or after treatment with levofloxacin (including a few weeks after treatment), may be symptoms of disease caused by Clostridium difficile (CDAD). CDAD can change from mild to severe that can be life -threatening, the most severe body of this disease is fake colitis. Therefore, it is necessary to consider the diagnosis for patients with serious diarrhea occurring during or after treatment with levofloxacin.

    If suspected or confirmed to have a CDAD, levofloxacin must be stopped and started appropriate treatment without delay. Treatment with intestinal peristaltic drugs is contraindicated in this clinical situation.

    Patients who are susceptible to diseases

    Quinolon can reduce the threshold of the disease and can stimulate diseases.

    Levofloxacin contraindicated in patients with a history of epilepsy and, as well as other quinolons, must be very careful when using drugs in patients who are susceptible to diseases or are being treated at the same time with active ingredients that may reduce the threshold of brain disease, such as theophylin. In cases where there are diseases with jerks, to stop treating with levofloxacin.

    Patients with glucose-6-phosphate dehydrogenase

    Potential or actually missing patients with glucose-6-phosphate dehydrogenase may have hemolytic reactions when treated with quinolon. Therefore, if you have to use levofloxacin in these patients, you must monitor the possibility of hemolysis.

    Patients with renal failure

    Because levofloxacin is out of the kidney, Tavanic's dose must be adjusted according to the degree of kidney failure.

    Hypersensitivity reactions

    levofloxacin can cause serious hypersensitivity reactions, potentially fatal (for example, a circuit up to anaphylactic shock), or sometimes follow a starting dose. Patients must stop treating immediately and consult with a doctor or an emergency doctor, so that this person will start appropriate emergency treatment measures.

    Severe blister reactions

    Cases of severe blistering skin reactions like Stevens Johnson's syndrome or poisoned necrosis. If the reactions occur in the skin and/or in the mucosa, the patient is advised to see a doctor immediately before continuing this medication.

    Blood sugar disorders

    Like other quinolones, blood sugar disorders include both hypoglycemia and hyperemms that have been reported, usually in diabetics used at the same time as an oral hypoglycemic drug (for example, glibenclamide) or with insulin. Cases of coma due to hypoglycemia have been reported. In diabetics, it is recommended to carefully monitor blood sugar.

    Prevention of increased light sensitivity

    Increased light sensitivity has been reported to levofloxacin. It is recommended that these patients do not dry themselves unnecessarily with strong sunlight or artificial ultraviolet rays (for example, sunlight, sunbathing room), during treatment and during 48 hours after stopping to prevent increased sun -sensitive sun.

    Patients treated with anti -vitamin K drugs

    Due to the ability to increase blood clotting tests (prothrombin/INR) and either bleeding in patients treated with levofloxacin at the same time with a vitamin K resistant (e.

    Mental reactions

    Psychiatric reactions have been reported in patients with quinolon treatment, including levofloxacin. Very rare cases of progress to the thoughts of suicide and self -dangerous behavior sometimes after just one dose of levofloxacin. In the case of patients with these reactions, levofloxacin should be discontinued and properly handled measures. Be careful if using levofloxacin in mental patients or in patients with a history of mental illness.

    extends the range of qt

    Be cautious when using fluoroquinolon, including levofloxacin, in patients with risk factors for extending QT about known as:

  • congenital QT syndrome. myocardial infarction, slow heart rate).
  • Elderly patients and women may be more sensitive to the known drugs that cause QT around. Therefore, it is necessary to be cautious when using fluoroquinolon, including levofloxacin, in these patient groups.

    Peripheral neuropathy

    Peripheral sensory neuropathy and peripheral sensory neuropathy have been reported in patients using fluoroquinolon, including levofloxacin, which can quickly onset. Levofloxacin should be stopped if the patient has symptoms of peripheral neuropathy to prevent progress to the loss of recovery.

    Liver disorders

    Cases of liver necrosis or fatal liver failure have been reported when taking levofloxacin, mainly in patients with diseases should be serious, for example: blood infections. The patient should stop treatment and contact the doctor if there are signs and symptoms of progressive liver disease such as anorexia, jaundice, dark urine, itching or abdominal pain when pressing.

    To worsen myasthenia gravis

    fluoroquinolon, including levofloxacin, is capable of choosing a nervous place and can weaken muscles in myasthenia patient. The serious adverse reactions after circulation of the drug, including death and need for respiratory help, occur with the use of fluoroquinolon in patients with myasthenia gravis. It is recommended not to use levofloxacin in patients with a history of myriadia.

    vision disorders

    If the vision is impaired or appears any impact on the eyes, the patient must advise with an eye expert immediately.

    superinfection

    The use of levofloxacin, especially if prolonged, can lead to excessive growth of non -sensitive organisms. If superinfection occurs during treatment, it is necessary to take appropriate evaluation measures.

    Change tests

    In patients treated with levofloxacin, the determination of opium in the urine can give a fake positive result. The scale uses more specific screening methods to confirm that the opium test is a real positive.

    levofloxacin can inhibit the growth of mycobacterium tuberculosis and therefore can give fake negative results in microbiological diagnosis for tuberculosis.

    Using drugs for women during pregnancy and lactation

    Pregnant women

    There are very little data on the use of levofloxacin in pregnant women. Animal studies do not show direct or indirect effects on reproductive toxicity.

    However, due to lack of human data, and due to experimental data shows that fluoroquinolon increases the risk of damage to the weight -resistant cartilage tissue of developing organisms, it is not allowed to use levofloxacin for pregnant women.

    breastfeeding women

    Tavanic is not only used in women who are breastfeeding. There is not enough information about the excretion of levofloxacin through breast milk; However, other fluoroquinolones are excreted through breast milk. Because of lack of data on humans and due to that empirical data, Fluoroquinolon increases the risk of damage to the cartilage tissue with the weight of developing creatures, so it is not allowed to use levofloxacin in breastfeeding women.

    fertility

    levofloxacin does not reduce fertility or reproduction in mice.

    The effect of the drug on the ability to drive and operate machinery

    Patients may experience side effects after using Tavanic, including the feeling of dizziness, drowsiness, dizziness, or visual disorders.

    Some of these side effects can reduce the ability to focus and react speed of the patient, and therefore can create risks in some important important situations.

    Drug interaction

    Tavanic can affect the impact of some other drugs. In contrast, some other drugs may affect the mechanism of Tavanic's action.

    The effect of other drugs on Tavanic

    Theophylin, fenbufen or non -steroid anti -inflammatory drugs are similar

    Notes without pharmacokinetic interaction between levofloxacin and theophylin in a clinical study. However, there is a significant reduction in the threshold of brain disease when using Quinolon at the same time with theophylin, non -steroid anti -inflammatory drugs, or other agents that reduce the threshold of the disease. Levofloxacin concentration will be about 13% higher when used with fenbufen compared to when only used individually.

    probenecid and cimetidine

    Probenecid and cimetidine have a significant impact on the elimination of levofloxacin. Levofloxacin's kidney clearance levels decreased by cimetidine (24%) and probenecid (34%). This is because both of these drugs have the ability to prevent levofloxacin excretion through the renal tubules. However, in these research doses in this study, the difference in pharmacokinetics has an uncertain statistical statistical significance clinically related.

    Be cautious when taking levofloxacin with drugs that affect renal excretion such as Probenecid and cimetidine, especially in patients with impaired renal function.

    Other related information

    Clinical pharmacological research has shown that levofloxacin pharmacokinetics are not affected by any clinical related level, when levofloxacin is used with the following drugs: Calcium carbonate, digoxin, glibenclamid, ranitidine.

    Tavanic's influence on other drugs

    cyclosporin

    The half -life of cyclosporin increased by 33% when used with levofloxacin.

    Vitamin K anti -vitamin drugs

    There has been an increase in blood clotting tests (PT/INR) and/or bleeding, which may be severe, in patients treated with levofloxacin at the same time with vitamin K anti -vitamin (e.g. warfarin). Therefore, blood clotting tests must be monitored in patients who are being treated with vitamin K anti -vitamin drugs.

    Known drugs cause extended QT

    levofloxacin, like other fluoroquinolon, should be used cautiously in patients who are taking the drug that has caused a long -term extension of QT (for example: IA and III anti -arrhythmic drugs, three -round antidepressants, macrolid, anti -psychotic drugs).

    Other related information

    In a pharmacokinetic interaction study, Levofloxacin does not affect the pharmacokinetics of theophylin (which is a substrate for CYP1A2 exploration), indicating that levofloxacin is not a CYP1A2 inhibitor.

    Cavalry or compatibility

    Tavanic infusion solution is not mixed with heparin or alkaline solutions (for example, sodium hydrogen carbonate).

    Tavanic infusion solution can be compatible with the following infusion solution: 0.9%sodium chloride solution; 5%Dextrose solution; Dextrose solution 2.5% in the ringer, solutions to nourish venous lines (amino acids, carbohydrates, electrolytes).

    Storage

    In a dry place, the temperature does not exceed 30 ° C, avoiding light.

    Other drugs

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    count views

    Popular Keywords